Colgrove, J., and R. Bayer. 2005. Could it happen here? Vaccine risk controversies and the specter of derailment. Health Affairs 24(3):729-739.
Cutts, F. T., S. M. A. Zaman, G. Enwere, S. Jaffar, O. S. Levine, J. B. Okoko, C. Oluwalana, A. Vaughan, S. K. Obaro, A. Leach, K. P. McAdam, E. Biney, M. Saaka, U. Onwuchekwa, F. Yallop, N. F. Pierce, B. M. Greenwood, and R. A. Adegbola. Efficacy of nine-valent pneumococcal conjugate vaccine against pneumonia and invasive pneumococcal disease in the Gambia: Randomised, double-blind, placebo-controlled trial. The Lancet 365(9465):1139-1146.
IOM (Institute of Medicine). 2008. Transcript of meeting one of the Committee on the Review ofPriorities in the National Vaccine Plan. Washington, DC.
IOM Staff. 2008. IOM staff notes: Major themes from conversations with key individualsknowledgeable about the process of preparing the 1994 National Vaccine Plan. Washington, DC.
Iskander, J. 2007. Current CDC vaccine safety activities. Presentation at Vaccine SafetyEvaluation: Post Marketing Surveillance Conference. Bethesda, MD.
Kaplan, R. S., and D. P. Norton. 1992. The balanced scorecard: Measures that drive performance. Harvard Business Review 70(1):71-79.
Klugman, K. P., S. A. Madhi, R. E. Huebner, R. Kohberger, N. Mbelle, N. Pierce, and the Vaccine Trialists Group. 2003. A trial of a 9-valent pneumococcal conjugate vaccine in children with and those without HIV infection. New England Journal of Medicine 349(14):1341-1348.
Lee, G. M., J. M. Santoli, and C. Hannan. 2007. Gaps in vaccine financing for underinsured children in the United States. Journal of the American Medical Association 298(6):638-643.
Milstien, J. B., M. Kaddar, and M. P. Kieny. 2006. The impact of globalization on vaccine development and availability. Health Affairs 25(4):1061-1069.
NIAID (National Institute of Allergy and Infectious Diseases). 1998. Task force on saferchildhood vaccines: Final report and recommendations. Bethesda, MD: National Institues of Health.
NVPO (National Vaccine Program Office). 1994. Disease prevention through vaccinedevelopment and immunization: The U.S. National Vaccine Plan—1994. Washington, DC: Department of Health and Human Services.
NVPO. 1997. NVPO Interagency group workshop agenda book. St. Michaels, MD: NVPO.
Orenstein, W. A. 2008. Draft priorities of the national vaccine plan. Presentation at Meeting Oneof the Committee on Review of Priorities in the National Vaccine Plan. Washington, DC.